✦ LIBER ✦

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

✍ Scribed by Argyriou, A. A.; Velasco, R.; Briani, C.; Cavaletti, G.; Bruna, J.; Alberti, P.; Cacciavillani, M.; Lonardi, S.; Santos, C.; Cortinovis, D.; Cazzaniga, M.; Kalofonos, H. P.

Book ID: 118208991
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 133 KB
Volume: 23
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mds208

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective validation pharmacogenomic

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen

✍ Cecchin, E; D'Andrea, M; Lonardi, S; Zanusso, C; Pella, N; Errante, D; De Mattia 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 385 KB

A Phase II Study of Oxaliplatin, 5-Fluor

A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer

✍ Sam J. Lubner; Noelle K. LoConte; Kyle D. Holen; William Schelman; James P. Thom 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 117 KB

636 POSTER Initial safety findings from

636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Bevacizumab plus FOLFIRI or FOLFOX as th

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

✍ Byung Woog Kang; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Chang 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 188 KB

An EORTC phase I study of Bortezomib in

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer

✍ F. Caponigro; D. Lacombe; C. Twelves; J. Bauer; A.-S. Govaerts; S. Marréaud; A. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 214 KB

6066 Phase II study of two doses of NGR-

6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens

✍ Sobrero, A.F.; Pessino, A.; Andretta, V.; Bennicelli, E.; Fornarini, G.; Caprion 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB